Polycystic Ovary Syndrome (PCOS) and Infertility

From a western clinical perspective, PCOS is a multifactorial endocrine disorder that disrupts ovulation and thereby contributes to subfertility. Insulin resistance, present in many with PCOS across the BMI spectrum, stimulates theca cells to produce excess androgens. In turn, hyperandrogenism impairs granulosa cell function and follicle maturation, and a relative increase in LH signaling favors androgen production over estradiol synthesis. The follicular cohort accumulates as small antral follicles—visible as polycystic ovarian morphology—without selection of a dominant follicle, leading to oligo- or anovulation. Endometrial receptivity can also be affected by metabolic and inflammatory changes. Diagnosis uses Rotterdam criteria (two of: ovulatory dysfunction, clinical/biochemical hyperandrogenism, polycystic ovaries) after excluding thyroid disease, hyperprolactinemia, non-classic congenital adrenal hyperplasia, and other mimickers. Anti-Müllerian hormone and transvaginal ultrasound help characterize ovarian reserve and morphology, while partner semen analysis is a standard early step in fertility evaluation. Prognosis hinges on age, BMI, and metabolic status; small improvements in weight and insulin sensitivity often translate into improved ovulation and better responses to treatment. Treatment follows a stepwise approach. Lifestyle optimization supports metabolic health and can restore spontaneous ovulation for some. Letrozole is generally first-line for ovulation induction in PCOS and outperforms clomiphene in live birth rates, while clomiphene remains a reasonable alternative. Metformin primarily addresses insulin resistance and can aid ovulation, especially in combination with clomiphene, and may reduce OHSS risk in IVF cycles. Low-dose gonadotropins are effective second-line options, requiring close ultrasound and hormonal monitoring to minimize multiple pregnancy. When these measures are insufficient or other factors coexist, IVF provides high success rates with single-embryo transfer; antagonist protocols and GnRH agonist triggers are preferred to lower OHSS risk in PCOS. Throughout, preconception optimization—blood pressure, glycemia, thyroid function, and a prenatal vitamin—supports healthy conception and pregnancy. Pregnancy in PCOS carries higher risks of gestational diabetes and hypertensive disorders, making early risk assessment and coordinated obstetric care important.

Traditional and integrative frameworks view PCOS-related infertility as a systemic pattern of disharmony that obstructs the menstrual-ovarian axis. In Traditional Chinese Medicine, phlegm-damp accumulation often corresponds to insulin resistance and weight gain; liver qi stagnation reflects stress-related cycle irregularity; and kidney deficiency parallels reduced reproductive vitality. Clinical practice individualizes treatment to the dominant pattern. Formulas that transform phlegm and move qi are combined with tonics to nourish kidney essence, aiming to restore regular ovulation. Acupuncture protocols commonly target pelvic blood flow and neuroendocrine regulation, while also addressing stress through points that calm the spirit. Modern studies suggest acupuncture may modulate hypothalamic–pituitary–ovarian signaling and improve insulin sensitivity, with mixed clinical results compared to established pharmacologic therapies. Ayurveda interprets PCOS as a Kapha-dominant imbalance with involvement of Vata and Pitta. Therapies emphasize kapha-reducing diet, gentle exercise, sleep hygiene, and herbs such as Shatavari (supporting reproductive tissue) and Ashoka (cycle regulation). Panchakarma and mind–body practices (yoga, pranayama, meditation) aim to reduce stress and improve metabolic balance. While historical and contemporary clinical reports describe improved cycle regularity and fertility, randomized trials remain limited and heterogeneous. In integrative care, eastern therapies complement biomedical treatment: acupuncture to reduce stress and support ovulatory function during letrozole or gonadotropin cycles; dietary and mind–body practices to improve insulin sensitivity and adherence; and carefully selected botanicals or inositol supplements coordinated with medical teams to minimize interactions. The shared goal is to harmonize internal regulation while leveraging evidence-based ovulation induction and ART when appropriate, informed by individual values, safety, and evolving evidence.